Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus
NEW YORK, January 6, 2026, 12:28 EST — Regular session Shares of Moderna Inc (MRNA.O) were up 10.7% at $35.60 in midday trading on Tuesday after BofA Global Research raised its price objective on the vaccine maker. The stock touched a session high of $36.25. Reuters The jump comes as investors weigh whether Moderna can turn its mRNA platform into steadier, seasonal revenue after the post-pandemic drop in COVID-19 vaccine demand. Traders have been sensitive to shifts in sell-side views as the company leans on new product launches and tighter spending to narrow losses. On Monday, Moderna said it filed